Antiangiogenic properties of a novel shark cartilage extract: Potential role in the treatment of psoriasis

Journal of Cutaneous Medicine and Surgery

Volumn 2, Issue 3, 1998, Pages 146-152

  Dupont, Éric ^a   Savard, Pierre E ^b   Jourdain, Camille ^c   Juneau, Christina ^a   Thibodeau, Alain ^a   Ross, Neil ^d   Marenus, Kenneth ^e   Maes, Daniel H ^e   Pelletier, Georges ^b   Sauder, Daniel N ^f  

^a Les Laboratoires Æterna Inc 1405   (Canada)

^b LAVAL UNIVERSITY   (Canada)

^c Dermatological Clinic   (Canada)

^d NATIONAL RESEARCH COUNCIL CANADA   (Canada)

^e Estee Lauder Inc   (United States)

^f SUNNYBROOK RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; COLLAGENASE; METALLOPROTEINASE;

ANGIOGENESIS; ANIMAL TISSUE; ARTICLE; BASEMENT MEMBRANE; CARTILAGE; CHICK EMBRYO; ENZYME ACTIVITY; NONHUMAN; PRIORITY JOURNAL; PSORIASIS; SHARK; TISSUE CULTURE; TOPICAL DRUG ADMINISTRATION; ULTRAFILTRATION;

EID: 0005485030     PISSN: 12034754     EISSN: None     Source Type: Journal    
DOI: 10.1177/120347549800200307     Document Type: Article

References (53)

1. Swanbeck G, Inerat A, Martinsson T, Wahlstrom J. A population genetic study of psoriasis. Br J Dermatol 1994; 131:32-39.
2. Krueger GG, Dunic M. Epidemiology of psoriasis: clinical issues. J Invest Dermatol 1994; 102:145-189.
3. Parent D, Bernard BA, Desbas C. Spreading of psoriatic plaques and alteration of epidermal differentiation precedes capillary leakiness and abormalities in vascular morphology. J Invest Dermatol 1990; 95:333-340.
4. Telner P, Fikete Z. The capillary responses in psoriatic skin. J Invest Dermatol 1961; 36:225-230.
5. Folkman JF. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333:1757-1763.
6. Wolf JE, Harrison RG. Demonstration and characterization of an epidermal angiogenic factor. J Invest Dermatol 1973; 59:40-43.
7. Eisenstein R, Kuettner KE, Neopolitan C, et al. The resistance of certain tissue to invasion. III. Cartilage extracts inhibit the growth of fibroblasts and endothelial cells in culture. Am J Pathol 1975; 81:337-347.
8. Pauli BU, Memoll VA, Kuettner K. Regulator of tumor invasion by cartilage-derived anti-invasion factor in vitro. J Natl Cancer Inst 1981; 67:65-73.
9. Moses MA, Sudhalter J, Langer R. Isolation and characterization of an inhibitor of neovascularization from scapular chondrocytes. J Cell Biol 1992; 119:475-482.
10. McGuire TR, Kazakoff PW, Hoie EB, Fienhold MA. Antiproliferative activity of shark cartilage with and without tumor necrosis factor-α in human umbilical vein endothelium. Pharmacotherapy 1996; 16:237-244.
11. Lee A, Langer R. Shark cartilage contains inhibitors of tumor angiogenesis. Science 1983; 221:1185-1187.
12. Folkman J, Klagshrun M. Angiogenic factors. Science 1987; 235:442-448.
13. Moses MA, Sudhalter J, Langer R. Identification of an inhibitor of neovascularization from cartilage. Science 1990; 248: 1408-1410.
14. Oikawa T, Ashino-Fuse H, Shimamura M, et al. A novel angiogenic inhibitor derived from Japanese shark cartilage. I. Extraction and estimation of inhibitory activities toward tumor and embryonic angiogenesis. Cancer Lett 1990; 51:181-186.
15. Moses MA. A cartilage-derived inhibitor of neovascularization and metalloproteinases. Clin Exp Rheumatol 1993; 11(Suppl. 8):S67-S69.
16. Langer R, Conn H, Vacanti J, et al. Control of tumor growth in animals by infusion of an angiogenesis inhibitor. Proc Natl Acad Sci USA 1980; 77:4331-4335.
17. Dupont E, Brazeau P, Juneau C. Extracts of shark cartilage having an antiangiogenic activity and an effect on tumor regression: process of making thereof. United States Patent No. 5,618,925, 1997.
18. Thomson AW, Ducan JL. The influence of cyclosporin A on T cell activation, cytokine gene expression and cell-mediated immunity. In: Thomson AW, ed. Cyclosporin: mode of action and clinical applications. Lancaster, England: Kurver Acad Publ 1989; 50-81.
19. 389 L-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995; 1:442-447.
20. Elder JT, Fisher GJ, Lindquist PB. Overexpression of transforming growth factor alpha in psoriatic epidermis. Science 1989; 243:811-814.
21. Detmar N, Brown LF, Claffey KP, et al. Overexpression of vascular permeability factor/vascular endothelium growth factor and its receptors in psoriasis. J Exp Med 1994; 180:1141-1146.
22. Gillitzer R, Berger R, Mielke V, et al. Upper keratinocytes of psoriatic skin lesions express high levels of NAR-1/IL-8mRNA in situ. J Invest Dermatol 1991; 97:73-79.
23. Sticherling M, Bornscheuer E, Schroder J-M, Christophers E. Localization of neutrophil-activating peptide-1/interleukin-8-immunoreactivity in normal and psoriatic skin. J Invest Dermatol 1991; 96:26-30.
24. Waelti ER, Inaebnit SP, Rast HP, et al. Co-culture of human keratinocytes on postmitotic human dermal fibroblast feeder cells: production of large amounts of interleukin 6. J Invest Dermatol 1992; 98:805-808.
25. Kojima T, Cromie MA, Fisher GJ, et al. GRO-A mRNA is selectively overexpressed in psoriatic epidermis and is reduced by cyclosporin A in vivo, but not in cultured keratinocytes. J Invest Dermatol 1993; 101:767-772.
26. Konstantinova NV, Duong D-MT, Remenyik E, et al. Interleukin-8 is induced in skin equivalents and is highest in those derived from psoriatic fibroblasts. J Invest Dermatol 1996; 107: 615-621.
27. Nickoloff BJ, Mitra RS, Varani J, et al. Aberrant production of interleukin-8 and thrombospondin-1 by psoriatic keratinocytes mediates angiogenesis. Am J Pathol 1994; 144:820-828.
28. Grant DS, Kleinman HK, Goldberg ID, et al. Scatter Factor induces blood vessel formation in vivo. Proc Natl Acad Sci USA 1993; 90:1937-1941.
29. Colville-Nash PR, Scott DL. Angiogenesis and rheumatoid arthritis: pathogenic and therapeutic implications. Ann Rheum Dis 1992; 51:919-925.
30. Norrby K. Cyclosporine is angiostatic. Experientia 1992; 48: 1135-1138.
31. Lipman RM, Epstein RJ, Hendricks RL, et al. Suppression of corneal neovascularization with cyclosporine. Arch Ophthalmol 1992; 110:405-407.
32. Li VW, Li WW. Cyclosporine and angiogenesis in psoriasis. J Am Acad Dermatol 1996; 35:1019-1020.
33. Atherton DJ, Wells RS, Laurent MR, Williams YF. Razoxane (ICRF 159) in the treatment of psoriasis. Br J Dermatol 1980; 102:307-317.
34. 3 treatment in psoriasis vulgaris. Br J Dermatol 1986; 115:421-429.
35. LeServe AW, Hellmann K. Metastases and the normalisation of tumour blood vessels by ICRF-159: a new type of drug action. BMJ 1972; 1:597-601.
36. Horton JJ, Wells RS. Razoxane: a review of 6 years therapy in psoriasis. Br J Dermatol 1983; 109:669-673.
37. Caffrey EA, Daker MG, Horton JJ. Acute myeloid leukemia after treatment with razoxane. Br J Dermatol 1985; 113:131-134.
38. Folkman J, Ingber DE. Angiostatic steroids. Ann Surg 1987; 206: 374-383.
39. Prudden JF, Hishihara G, Baker L. The acceleration of wound healing with cartilage. I. Surg Gynecol Obstet 1957; 105:283-286.
40. Houck JC, Jacob RA, DeAngelo L, Vickers K. The inhibition of inflammation and the acceleration of tissue repair by cartilage powder. Surgery 1962; 51:632-638.
41. Prudden JF, Allen J. The clinical acceleration of healing with a cartilage preparation. JAMA 1965; 192:352-356.
42. Sabo JC, Enquist IF. Wound-stimulating effect of homologous and heterologous cartilage. Arch Surg 1965; 91:523-525.
43. Sabo JC, Oberlander L, Enquist IF. Acceleration of open wound healing by cartilage. Arch Surg 1965; 90:414-417.
44. Prudden JF, Wolarsky ER, Balassa L. The acceleration of healing. Surg Gynecol Obstet 1969; 128:1321-1326.
45. Prudden JF, Migel P, Hanson P, et al. The discovery of a potent pure chemical wound-healing accelerator. Am J Surg 1970; 119: 560-564.
46. R for the treatment of degenerated skin in females. J Int Med Res 1991; 19:147-152.
47. Heule F. An oral approach to the treatment of photodamaged skin: a pilot study. J Int Med Res 1992; 20:273-278.
48. Eskelinin A, Santalahti J. Special natural cartilage polysaccharides for the treatment of sun-damaged skin in females. J Int Med Res 1992; 20:99-105.
49. Eskelinin A, Santalahti J. Natural cartilage polysaccharides for the treatment of sun-damaged skin in females: a double-blind comparison of "Vivida" and "Imedeen." J Int Med Res 1992; 20: 227-233.
50. Kuettner KE, Hiti J, Eisenstein R, Harper E. Collagenase inhibition by cationic proteins derived from cartilage and aorta. Biochem Biophys Res Commun 1976; 72:40-46.
51. Sadove AM, Keuttner KE. Inhibition of mammary carcinoma invasiveness with cartilage-derived inhibitors. Surg Forum Orthopaed Surg 1977; 28:499-501.
52. Knight CG, Willenbrock F, Murphy G. A novel coumarinlabelled peptide for sensitive continuous assays of the matrix metalloproteinases. FEBS Lett 1992; 296:263-266.
53. Weingarten H, Martin R, Feder J. Synthetic substrates of vertebrate collagenases. Biochemistry 1985; 24:6730-6734.